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Abstract
Background: We studied anomalous extracellular mRNAs in plasma from patients with diffuse large B-cell lymphoma
(DLBCL) and their survival implications. mRNAs studied have been reported in the literature as markers of poor (BCL2,
CCND2, MYC) and favorable outcome (LMO2, BCL6, FN1) in tumors. These markers were also analyzed in lymphoma tissues to
test possible associations with their presence in plasma.
Methodology/Principal Findings: mRNA from 42 plasma samples and 12 tumors from patients with DLBCL was analyzed by
real-time PCR. Samples post-treatment were studied. The immunohistochemistry of BCL2 and BCL6 was defined. Presence
of circulating tumor cells was determined by analyzing the clonality of the immunoglobulin heavy-chain genes by PCR. In
DLBCL, MYC mRNA was associated with short overall survival. mRNA targets with unfavorable outcome in tumors were
associated with characteristics indicative of poor prognosis, with partial treatment response and with short progression-free
survival in patients with complete response. In patients with low IPI score, unfavorable mRNA targets were related to shorter
overall survival, partial response, high LDH levels and death. mRNA disappeared in post-treatment samples of patients with
complete response, and persisted in those with partial response or death. No associations were found between circulating
tumor cells and plasma mRNA. Absence of BCL6 protein in tumors was associated with presence of unfavorable plasma
mRNA.
Conclusions/Significance: Through a non-invasive procedure, tumor-derived mRNAs can be obtained in plasma. mRNA
detected in plasma did not proceed from circulating tumor cells. In our study, unfavorable targets in plasma were
associated with poor prognosis in B-cell lymphomas, mainly MYC mRNA. Moreover, the unfavorable targets in plasma could
help us to classify patients with poor outcome within the good prognosis group according to IPI.
Citation: Garcia V, Garcia JM, Silva J, Martin P, Pen ˜a C, et al. (2009) Extracellular Tumor-Related mRNA in Plasma of Lymphoma Patients and Survival
Implications. PLoS ONE 4(12): e8173. doi:10.1371/journal.pone.0008173
Editor: Patrick Tan, Duke-NUS Graduate Medical School, Singapore
Received June 30, 2009; Accepted November 2, 2009; Published December 15, 2009
Copyright:  2009 Garcia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the following grants: Instituto de Salud Carlos III (FIS)-PI04/0053 and (RETIC) RD06/0020/0020; MICINN (SAF) 2004-01002
and SAF 2007-60214. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: fbonilla.hpth@salud.madrid.org (FB); mprovencio.hpth@salud.madrid.org (MP)
Introduction
DLBCL accounts for approximately 30% of new diagnoses and
more than 80% of aggressive lymphomas. Recently, anti-CD20
monoclonal antibody (rituximab) has been combined with CHOP,
which has improved survival [1]. DLBCL is a non-uniform
subgroup of tumors with a variety of clinical presentations,
outcomes, response to treatment and genetic alterations. This
could be because DLBCL consists of several diseases, but
stratification into subclasses by standard pathologic techniques
has not been possible. Thus, studies about individual prognostic
markers and prognostic models based on the combination of
several markers have been performed, so increasing the insights of
molecular heterogeneity [2]. There is disparity between the genes
that comprise the predictive models of the studies, which could be
due to different criteria for patient selection and statistical
algorithms used for their construction [2]. In an attempt to devise
a technically simple model, Lossos and colleagues evaluated 36
genes found to be predictive of outcome in gene array studies and
created a prediction model validated in these previous studies [3].
Cell-free nucleic acids derived from tumors are detectable in
plasma of cancer patients and may show diagnostic and prognostic
values [4,5]. The use of these markers in plasma as a source of
tumor information would be important, since they are obtained by
a non-invasive method that would be useful during patients’
follow-up and treatment monitoring. To our knowledge, there are
few studies of lymphoma that analyze nucleic acids in plasma.
Epstein-Barr virus DNA, rearranged immunoglobulin heavy chain
DNA and telomerase mRNA, in a preliminary study, were
detected in plasma from patients with lymphomas [6–8]. Thus, the
prognostic value of mRNA detected in plasma from DLBCL
patients is a novel approach.
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8173This is the first study analyzing mRNA in plasma from patients
with DLBCL. In this study, we analyzed plasma mRNA of three
‘‘unfavorable’’ genes, which have been described as markers of
poor outcome and components of the activated B-cell signature
(CCND2, BCL2 and MYC), and three ‘‘favorable’’ genes, which
have been described as markers of good outcome and components
of the germinal-center B-cell signature (BCL6 and LMO2) and
lymph-node signature (Fibronectin 1). These unfavorable and
favorable markers (both mRNA and protein) have been studied
in individually and/or in a large data set in DLBCL tissues and
have been associated with shorter and longer survival, respectively
[2]. In the study of Lossos and colleagues [3] evaluating 36 genes,
our markers showed high absolute univariate z scores. Analysis of
plasma mRNA of the six genes was performed using real-time
polymerase chain reaction (RT-PCR). We investigated whether
these markers in plasma were associated with progression-free
survival (PFS), overall survival (OS), a series of clinico-pathological
parameters and treatment response. The possible relation between
plasma mRNA and circulating tumor B-cells was studied.
Moreover, we analyzed the levels of mRNA and BCL2 and
BCL6 protein in DLBCL tumor tissues by PCR and immunohis-
tochemistry (IHC), respectively.
Materials and Methods
Patients and Clinical Characteristics
We recruited prospectively 42 DLBCL patients with a
median follow-up of 13.7 months (range: 3–35 months), 25
Follicular Lymphoma (FL) cases and 16 with Hodgkin’s
lymphoma (HL). Samples were provided mainly by Puerta de
Hierro Majadahonda University Hospital, with the collabora-
tion of four other Spanish hospitals. Informed written consent
was obtained from all participants after an explanation of the
nature of the study, as approved by the research ethics board of
Puerta de Hierro Majadahonda University Hospital acting as
reference ethics board for the other five hospitals, in line with
Spanish legislation in cases of collaborative research studies.
The histological diagnosis was ascertained by lymph node
biopsy. Blood samples were taken before the treatment began.
Between 4 and 6 weeks after treatment, blood samples were
taken from 13 patients with DLBCL. Blood samples from 50
healthy blood donors were obtained at the hematology unit of
our hospital. Paraffin blocks from 26 DLBCL tumors were
selected only on the basis of the availability of suitable formalin-
fixed, paraffin-embedded tissue. Twelve out of 26 blocks had
enough material to extract RNA.
At diagnosis, the following data were available: age, sex, stage,
histological grade, ‘‘B’’ symptoms, number of affected lymph node
regions, extranodal involvement, bone marrow infiltration,
performance status, bulky disease, detection of Hepatitis C Virus,
standard hematological tests and levels of LDH, b2-microglobulin
and albumin. The International Prognostic Index (IPI) and FLIPI
(for FL) scores were determined.
Clinical Follow-Up and Treatment
Prospective follow-up, starting after diagnosis and treatment,
was based on regular (every 3 months during the first and second
year, every 6 months during the third year, and then yearly until
relapse) clinical, biochemical and radiological examinations (chest
and abdominal CT), gallium scan and MNR or PET if suggested
by radiologists. OS and PFS were defined as the period from time
of diagnosis until death and the interval between the start of
treatment and disease progression or recurrence. In DLBCL, 32
patients received CHOP-Rituximab (CHOP-R) and 10 patients
received CHOP-R plus radiotherapy. In FL, 14 patients were
treated with CHOP-R, 3 with CVP-R, 2 with radiotherapy, 2 with
CHOP-R plus radiotherapy and 4 patients with low tumor burden
were managed with a ‘‘watch and wait’’ policy. In HDK, 8
patients received chemotherapy (ABVD), one received radiother-
apy and 7 received ABVD plus radiotherapy. CHOP-R consists of
cyclophosphamide, doxorubicin, vincristine, prednisone and
rituximab, administered to the standard doses for this regimen.
CVP-Rituximab is like the previous regimen without doxorubicin.
The ABVD regimen consists of adriamycin, bleomycin, vinblastine
and dacarbazine.
Plasma Processing, mRNA Isolation and Real-Time PCR
Blood samples were stored at 4uC for 24 hours and were
subsequently processed by two centrifugations (3006g and
2,0006g for 30 min each one). Plasma samples were carefully
divided in aliquots of 1 ml and snap frozen at 280uC until
processing.
mRNA was obtained from 1 ml of plasma by Dynabeads
mRNA DIRECT Kit. Plasma was incubated with 100 mlo f
Dynabeads Oligo (dT) for 10 min at room temperature, and
mRNA eluted in 10 mM Tris-HCl. mRNA from 12 paraffin-
embedded tumors, was isolated by RNeasy FFPE Kit (Qiagen
Inc., Hilden, Germany), according to the manufacturer’s instruc-
tions. mRNA was reverse-transcribed with the Gold RNA PCR
Core Kit (PE Biosystems, Foster City, CA) using random
hexamers, according to the manufacturer’s instructions.
For RT-PCR, PGK1, SDHA and UBC (common housekeeping
in tumor studies) were evaluated, but their expression in plasma
was not stable. Recently, an active release mechanism has been
suggested to explain the presence of mRNA in plasma [9–11],
which could explain the inadequacy of PGK1, SDHA and UBC as
housekeeping genes in studies that determine free mRNA in
plasma of cancer patients. In the absence of housekeeping genes,
quantitative data cannot be analyzed. For this reason, we analyzed
the target mRNAs as presence or absence in plasma. For the study
of tumor tissues, mRNA levels were normalized by using
Phosphoglycerate kinase 1 (PGK1) as housekeeping gene. RT-PCR
was performed in a LightCycler 480 Instrument using the
LightCycler 480 SYBR Green I Master Kit (Roche Diagnostics,
Mannheim, Germany), according to the manufacturer’s instruc-
tions. Primers are shown in Table S1. mRNA analysis was
performed in duplicate. Melting curve analyses and sequencing in
an ABI Prism
TM 377 DNA sequencer apparatus (PE Applied
Biosystems, Foster City, CA) confirmed the generation of the
specific PCR product expected.
Circulating Tumor Cell Analysis
Total mononuclear cells (MNC) were isolated from the
blood of study subjects by Ficoll (Lymphoprep, Axis-Shield
PoC AS, Norway) density gradient centrifugation. DNA was
obtained by DNeasy Blood and Tissue Kit (Qiagen Inc.,
Hilden, Germany), according to the manufacturer’s instruc-
tions. DNA samples obtained from MNC were used to
determine clonality of the immunoglobulin heavy-chain genes
(IgH) using BIOMED-2 primers by PCR [12]. IgH gene
rearrangement was studied, including seven reactions targeting
IgH-FR2 (framework region 2) and another seven reactions
targeting IgH-FR3 (framework region 3). PCR analysis was
done in ABI Genescan (ABI 310 PRISM sequencer), with IgH-
F R 2a m p l i f i c a t i o nt a k e na si nt h o s ec a s e sw i t has i n g l ep e a ko f
250–295 pb and IgH-FR3 amplification, in those cases with a
single peak of 100–170 pb.
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Tumor sections were immunostained with monoclonal anti-
bodies against BCL2 (clone 124; DAKO, Glostrup, Denmark) and
BCL6 (clone PG-B6p DAKO, Glostrup, Denmark). Nuclear
staining of 30% of neoplastic cells was used to define a case
positive for BCL6, whereas the cutoff used to determine BCL2
over-expression was 50% [13].
Data Analysis
x
2 test, Mann-Whitney, Kaplan-Meier and Mantel’s log-rank
test were used for statistical analysis. p values #0.05 were
considered statistically significant. Statistical analysis used the
SPSS, version 13.0 statistical software (SPSS Inc. Chicago, IL).
Results
Detection of mRNA in Plasma, Circulating Tumor Cells
and Tumor Tissues
In plasma from 42 patients with DLBCL, extracellular mRNA
of CCND2, BCL2, MYC, LMO2, BCL6 and FN1 was detected,
respectively, in 14%, 10%, 10%, 10%, 5% and 2% of them.
However, no plasma from 50 healthy controls showed presence of
all mRNAs, except one case of CCND2. Thus, a significant
difference was found between patients and controls in BCL2,
CCND2, MYC and LMO2 mRNA (p=0.026, p=0.027, p=0.026
and p=0.026, respectively; x
2test; Table S2). The molecular
markers were also analyzed in plasma from 25 patients with FL
and 16 with HL to test differences with DLBCL, detecting a
percentage of positive cases lower than in DLBCL, though the
differences are not significant (Table S3). In FL and HL, these
markers were not associated with response to treatment and
survival.
PCR was performed to determine presence of circulating tumor
B-cell monoclonality (FR2, FR3) in MNC from 27 DLBCL
patients. Clonality was detected in only one patient from this series
(Figure S1), 25 cases were polyclonal and in one case FR3 and
FR2 fragments were not amplified. The patient with circulating
tumor B-cell monoclonality showed bone marrow infiltration and
presence of mRNA in plasma. In the series analyzed, bone
marrow infiltration was also detected in another patient, but
clonality in MNC was not found. In conclusion, presence of
circulating tumor B-cells was not associated with presence of
mRNA in plasma.
BCL2, MYC, CCND2, BCL6 and LMO2 expression was studied
in tumor tissue from 12 DLBCL patients of our series using real-
time PCR. FN1 expression was not analyzed due to that the 12
tissues obtained showed absence of FN1 mRNA in plasma. mRNA
of all genes was detectable in all tissue samples. We analyzed the
possible associations between levels of mRNA in tumor tissues and
detection in plasma for each marker (Figure S2). BCL2 mRNA in
plasma was detected in those patients with higher levels of BCL2
expression in tumors (p=0.021; Mann-Whitney test). We found no
more associations with the others markers studied. Moreover, we
observed an association between high levels of BCL2 expression in
tumors and high IPI score, and a trend to signification with patient
who died (p=0.007 and p=0.086, respectively: Mann-Whitney
test).
Tumor-Related mRNA in Plasma and Patients’ Survival
Overall survival. Patients with presence of MYC and CCND2
mRNA in plasma had shorter survival than patients without them
(p,0.001 and p=0.09, respectively; Kaplan-Meier test; Figure 1).
No significant difference in OS was found for the rest of mRNAs
analyzed. When we eliminated the censured cases with a follow-up
below 12 months, we found a statistical significance for BCL2 and
MYC mRNA (p=0.003 for both).
Progression-free survival. The Kaplan-Meier test only
revealed a trend to significant association between detection of
MYC mRNA in plasma and patients with short PFS (p=0.099;
Kaplan-Meier test). Nor did this change, when we eliminated the
censured cases with follow-up below 12 months.
Tumor-related mRNA in plasma and overall survival in
low-risk patients according to IPI. In our patients with low-
risk IPI (0–2 IPI score; N=28), a significant difference, with worse
OS when CCND2 and MYC mRNA were present in plasma, was
observed (p=0.015 and p,0.001, respectively; Kaplan-Meier test;
Figure 2). In these patients, presence of MYC mRNA in plasma
was associated with partial response to treatment (p=0.011,
x
2test). We found an association close to significance between high
LDH levels and presence of CCND2, MYC or BCL6 mRNA in
plasma (p=0.068 for the 3 mRNA, x
2test). The relationship with
high LDH levels was significant with presence of at least one
unfavorable molecular marker (p=0.023, x
2test). Presence of at
least one favorable molecular marker was associated with absence
of extranodal involvement (p=0.039, x
2test). Finally, all low-risk
patients with CCND2 mRNA in plasma died during the follow-up
period (p=0.002, x
2test).
Figure 1. Kaplan-Meier OS curves in relation to presence of MYC and CCND2 mRNA in plasma.
doi:10.1371/journal.pone.0008173.g001
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Our DLBCL patients were treated with rituximab-CHOP and
66% of them had complete response to treatment. Presence of
BCL2 and MYC mRNA in plasma showed a trend to significant
association with partial response in patients with DLBCL (p=0.07
for both;x
2test; Table1).When we analyzed the presence ofat least
one marker of poor prognosis, the association with partial response
was stronger (p=0.059, x
2test). Presence of LMO2 mRNA in
plasma was not significant (p=0.13, x
2test), but, interestingly, all
positive cases had complete response. The rest of mRNA analyzed
showed no significant associations with response to treatment.
In plasma from patients with complete response to treatment,
we observed that patients with presence of CCND2, BCL2 or MYC
mRNA had shorter PFS than patients without these markers
(p=0.037, p=0.016, p=0.016, respectively; Kaplan-Meier test;
Figure S3).
Correlation of Tumor-Related mRNA in Plasma with
Clinico-Pathological Characteristics
We analyzed the possible associations between our molecular
markers and the clinico-pathological parameters of the tumors
(Table 1). Presence of BCL2, CCND2 and MYC mRNA in plasma
was associated with several characteristics of poor prognosis. When
presence of LMO2 mRNA was analyzed, we only observed a trend
to significant associations with characteristics of good prognosis.
BCL6 and FN1 mRNA were not associated with any parameter.
Immunohistochemistry Analysis
Immunohistochemistry analysis for BCL2 and BCL6 was
performed on tumor tissue from 24 and 26 DLBCL patients,
respectively, in our series (Figure 3). BCL2 and BCL6 expression
were detected in 54% and 89% of the tumors, respectively. BCL2
and BCL6 expression were not associated with detection of BCL2
and BCL6 mRNA in plasma, respectively. However, absence of
BCL6 expression in tumors was associated with presence of BCL2,
CCND2 and MYC mRNA in plasma (p=0.009, p=0.001 and
p=0.009, respectively; x
2test). Moreover, absence of BCL6
expression in tumors was associated with extranodal involvement
(p=0.047), high IPI score (p=0.006) and ‘‘B’’ symptoms
(p=0.002), and with short overall survival (p=0.011; x
2 and
Kaplan-Meier test).
Presence of Tumor-Related mRNA in Plasma from
Patients after Chemotherapy Treatment
Plasma obtained from 13 patients with DLBCL after treatment
was analyzed. Presence of BCL2, CCND2, MYC and BCL6 mRNA
Figure 2. Kaplan-Meier OS curves in relation to presence of MYC (A) and CCND2 (B) mRNA in plasma from patients classified
according to IPI.
doi:10.1371/journal.pone.0008173.g002
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response to treatment and subsequently died (p=0.015 for the four
mRNA; x
2test). LMO2 mRNA in post-treatment plasma was
detected in two patients who died (p,0.001, x
2test). In the patients
with complete response, presence of BCL2, CCND2, MYC and
BCL6 mRNA detected before treatment was lost in post-treatment
samples.
Discussion
LMO2, BCL6 and FN1 mRNA in lymphoma correlated with
prolonged survival [2], but when we detected them in plasma, no
differences with healthy controls or associations with favorable
o u t c o m ew e r ef o u n d ,e x c e p tf o rLMO2 mRNA. This could be
explained because the release of free nucleic acids into plasma for
tumor cells is a characteristic of poor outcome, which might
overcome the good prognostic value of these mRNA within the
lymphoma cells. When we studied mRNA in plasma of poor-
prognosis genes in tumors (MYC, CCND2 and BCL2) [2], patients
with presence of these mRNA in plasma have clinical and
biochemical features indicative of poor prognosis and short
survival. These results suggest that unfavorable molecular
markers described in tumors [2], mainly MYC mRNA, could
similarly be markers of poor outcome if they are found in plasma.
Our results suggested that the markers found in plasma from
DLBCL relating to poor outcome had lower prognostic value in
B-cell lymphoma with slow proliferation (FL) and, overall, with
HL.
Table 1. Associations between clinicopathological characteristics and presence of mRNAs in plasma from patients with DLBCL (x
2
test).
BCL2 mRNA CCND2 mRNA MYC mRNA LMO2 mRNA
+ (%) 2 (%) p + (%) 2 (%) p + (%) 2 (%) p + (%) 2 (%) p
Age
,60 2.5 31.7 NS 0 34.2 0.056 2.5 31.7 NS 7.3 26.8 0.070
$60 7.3 58.5 14.6 51.2 7.3 58.5 2.5 63.4
Grade
Intermediate 2.4 39 NS 0 41.5 0.026 0 41.5 0.076 4.9 36.6 NS
High 7.3 51.3 14.6 43.9 9.7 48.8 4.9 53.6
LNA
,4 5.9 70.6 NS 8.8 67.7 NS 5.9 70.6 NS 8.8 67.7 NS
$4 5.9 17.6 8.8 14.7 5.9 17.6 2.9 20.6
EI
Absence 4.9 43.9 NS 2.4 46.4 NS 4.9 43.9 NS 7.3 41.5 NS
Presence 4.9 46.3 12.2 39 4.9 46.3 2.4 48.8
BMI
Negative 8.6 82.9 NS 5.7 85.7 NS 5.7 85.7 NS 11.4 80 NS
Positive 2.8 5.7 2.9 5.7 2.9 5.7 0 8.6
LDH
Normal 4.9 53.6 NS 2.4 56.1 0.024 2.4 56.1 NS 9.8 48.8 0.076
High 4.9 36.6 12.2 29.3 7.3 34.2 0 41.4
IPI
Low-risk (0–2) 2.4 65.9 0.050 4.9 63.4 0.046 4.9 63.4 NS 7.3 61 NS
High-risk (3–5) 7.3 24.4 9.8 21.9 4.9 26.8 2.4 29.3
RT
Complete 2.5 63.4 0.070 7.3 58.5 NS 2.5 63.4 0.070 9.8 56.1 NS
Partial 7.3 26.8 7.3 26.9 7.3 26.8 0 34.1
LRS
Without disease 0 67.7 0.008 6.5 61.3 NS 0 67.7 0.034 9.7 58.1 NS
With disease 9.7 22.6 3.2 29 6.5 25.8 0 32.2
VSG
Normal 0 43.3 NS 0 43.3 0.060 0 43.3 NS 3.3 40 NS
Anormal 6.7 50 13.3 43.3 10 46.7 NS 6.7 50
Albumine
Nomal 5.1 82.1 0.019 10.3 76.9 NS 5.1 82.1 0.019 7.7 79.5 NS
,4 5.1 7.7 5.1 7.7 5.1 7.7 2.6 10.2
+: presence in plasma; 2: absence in plasma; LNA: number of lymph nodes affected; EI: extranodal involvement; BMI: bone marrow infiltrated; RT: response to
treatment; LRS: last revision status.
doi:10.1371/journal.pone.0008173.t001
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released by circulating tumor cells [14,15]. However, we only
found one patient with presence of circulating tumor B-cell
monoclonality. Recently, several studies have reported that
mRNA is released by an active mechanism in tumor cells [9–11].
Patients with presence of BCL2, CCND2, BCL6 and LMO2
mRNA in plasma showed higher expression levels for each gene in
tumor tissue, although we only observed a significant association
for BCL2 mRNA. In the literature, approximately 47% to 58% of
DLBCL tumors express BCL2 protein and 56% to 70% express
BCL6 protein [16]. Our results are similar, although BCL6 is
more expressed in our series. We found no association between
levels of BCL2 and BCL6 protein in tumors and presence of BCL2
and BCL6 mRNA in plasma. In a recent study, high expression of
BCL6 in tumors analyzed immunohistochemically was associated
with better overall survival in patients treated with CHOP and
with R-CHOP [17]. In our study, BCL6 over-expression in
tumors was a marker of favorable outcome. Curiously, expression
of BCL6 protein was related to absence of the unfavorable markers
we studied in plasma. Thus, presence of unfavorable mRNAs in
plasma is found in patients with poor outcome.
The IPI is established as one of the best predictors of outcome
[18]. However, variable survival of patients with identical
prognostic scores is found. In our study, presence of unfavorable
mRNA in plasma from patients with low risk (0–2 IPI score) was
associated with poor-prognosis characteristics and shorter overall
survival. Our results suggest that plasma mRNA could be used as a
molecular marker that identifies patients with poor prognosis in a
subset of patients clinically classified in a favorable outcome.
Tumors with similar cell phenotypes, classified with the same IPI
score, could have different capacities for active liberation of
mRNA into plasma, which could be interpreted as a more
aggressive characteristic of some of these lymphomas. Thus,
finding molecular features such as extracellular mRNAs of
unfavorable genes, which identify patients with poor outcome
within a low IPI, is an important objective.
An improvement in survival of patients with DLBCL when
rituximab was added to CHOP chemotherapy has led to its use as
Figure 3. Morphologic features and IHC expression in representative DLBCL patients. A) DLBCL anaplastic variant (H&E staining x20). B)
Lymph node section (H&E staining x20). IHC for BCL2 (x40) showing: C) Neoplastic cells negative for BCL2 and D) Strong cytoplasmic staining. IHC for
BCL6 (x40) showing: E) BCL6 negative case and F) BCL6 positive case with strong nuclear staining.
doi:10.1371/journal.pone.0008173.g003
Plasma mRNA in Lymphoma
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8173the new standard of care [1]. When several prognostic markers
were re-evaluated in the rituximab era, the prognostic values
appeared to be mitigated or transformed, as happened with BCL6
behavior [2]. For this reason, identification of new prognostic
factors in patients receiving rituximab is important. Our results
suggest that detection of unfavorable markers in plasma, such as
MYC or BCL2 mRNA, could be possible markers of poor outcome
and no response to treatment in the rituximab era. In addition,
disappearance of circulating mRNAs after chemotherapy was
observed in patients with complete response, while their
persistence was associated with partial response and death. These
results could indicate an active tumor origin of mRNAs in plasma
and could introduce the molecular remission concept, just as has
been established in the follow-up of some leukemias.
In conclusion, the presence of circulating nucleic acids in
patients with DLBCL could lead to the development of non-
invasive methods, useful for distinguishing tumors with different
clinical features, treatment response and outcome in the rituximab
era. Only the markers with unfavorable prognosis in tumors kept
their prognostic value in plasma. In particular, MYC mRNA could
be a marker of poor outcome and partial response to R-CHOP.
Moreover, our unfavorable markers in plasma showed differences
between lymphoma subtypes: they were more characteristic of B-
cell tumors with high proliferation. Finally, in patients clinically
classified in the good prognosis group by IPI, presence of mRNA
in plasma, such as MYC and CCND2 mRNA, could indicate a
subgroup of patients with poor outcome.
Supporting Information
Figure S1 Genescan analysis of DNA isolated from MNC
amplified with FR3 primers of IgH. A: monoclonal sample with a
single peak. B: polyclonal sample with many IgH PCR products.
C: positive monoclonal control. D: polyclonal control. E: negative
sample without DNA.
Found at: doi:10.1371/journal.pone.0008173.s001 (0.20 MB TIF)
Figure S2 Box plots showing the relationship between levels of
mRNA in tumor tissues (Normalized Relative Ratio) and detection
in plasma for each marker studied. The graphs show the quartiles
25, 50, and 75, values lower than 1.5 box lengths, and the outliers.
Found at: doi:10.1371/journal.pone.0008173.s002 (0.05 MB TIF)
Figure S3 Kaplan-Meier PFS curves in relation to presence of
BCL2, CCND2 and MYC mRNA in plasma of DLBCL patients
with complete response to chemotherapy.
Found at: doi:10.1371/journal.pone.0008173.s003 (0.05 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0008173.s004 (0.03 MB
DOC)
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